Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Teva Pharmaceutical Industries Ltd. (TEVA), Celltrion, Team Up To Market mAb Biosimilars

Page 1 of 2

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) recently entered into an exclusive agreement with Celltrion, Inc. to commercialize P10 and CT-P6, the latter’s two monoclonal antibody (mAb) biosimilar candidates. The deal covers North America.

medication, pharmacist, shelf, care, pharmaceutical, medical, day, drug, clinic, medicament, drugstore, treatment, ill, smiling, medicine, pharmaceutics, of, hospital,

wavebreakmedia/Shutterstock.com

New Partnership

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will pay $160 million to Celltrion in an upfront payment. A maximum $60 million of the upfront payment is refundable under certain circumstances. Both companies will share the resulting revenues in North America. John Carroll, a biotech analyst, tweeted the following yesterday on the deal:

Page 1 of 2
Loading Comments...